openPR Logo
Press release

Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Designations and Developments

09-11-2018 03:25 PM CET | Health & Medicine

Press release from: P&S Intelligence - Pharmaceuticals

Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical

Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis/report-sample

According to the research findings, a majority of the drug candidates for the treatment of hyperlipidemia are being developed to be administered by the oral route, which is convenient to take, and has been considered as non-invasive, often safer route that requires no special training to the patients.

It has been observed that most of the companies are developing drug candidates that involves novel target. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, Inclisiran is under the Phase III stage of development by The Medicines Company for the treatment of hyperlipidemia. The drug candidate is an RNAi that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) protein and RNA interference. It was found that Inclisiran cause sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.

Browse report at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis

Similarly, LY3015014 is under the Phase II stage of development by Eli Lilly and Company that target PCSK9 protein inhibitor. DCR-PCSK9 is a Pre-Clinical drug candidate of Dicerna Pharmaceuticals Inc.

Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Designations and Developments here

News-ID: 1233662 • Views:

More Releases from P&S Intelligence - Pharmaceuticals

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials and Developments
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaborations
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.

All 5 Releases


More Releases for Hyperlipidemia

Hyperlipidemia Drug Market Trends, Research Report, Growth, Opportunities, Forec …
The global hyperlipidemia drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the global hyperlipidemia market during the forecast period is the rapidly growing consumption of dairy products along with the sedentary lifestyle is fueling the market. Statins are the first line of treatment for hyperlipidemia. The expiration of patents of branded drugs will lead to the genericization
Hyperlipidemia Drugs Market Size - Forecasts to 2026
As per the research conducted by GME, the Hyperlipidemia Drugs Market is estimated to be valued at USD 21.84 Billion in 2021 and is projected to reach USD 24.71 Billion by 2026 at a CAGR of 2.5%. increasing unusual cholesterol levels, upsurge in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) level cost-effective innovations, growing public awareness of nutraceuticals, increasing innovations in biotechnology, government initiatives, and increasing research and developments activities
Global Hyperlipidemia Drug Market Size, Comprehensive Analysis & Forecast to 202 …
The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available
Hyperlipidemia Drugs Market - Operational challenges 2028 | Dr. Reddy's Laborato …
Global Hyperlipidemia Drugs Market: Overview Hyperlipidemia is a technical term for abnormal amounts of fats (lipids) in the blood. The two noteworthy sorts of lipids found in the blood are triglycerides and cholesterol. Triglycerides are made when your body stores the additional calories it doesn't require for producing energy. They additionally come specifically from a man's eating routine in nourishments, for example, red meat and entire fat dairy. An eating regimen
Hyperlipidemia Prescription Drugs Market To Witness Exponential Growth By 2019
Hyperlipidemia refers to abnormal elevation of lipids and/or lipoprotein levels. Risk factors associated with such condition include stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension and other cardiovascular diseases. Drugs which are used to treat hyperlipidemia act by either accelerating the elimination of lipoproteins from the body or decrease production of lipoproteins. These medications not only lower the unwanted cholesterol levels but also prove to be vital for lowering the
Hyperlipidemia Prescription Drugs Market by Technology, Application, Type & Geog …
This report provides in depth study of “Hyperlipidemia Prescription Drugs market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Hyperlipidemia Prescription Drugs Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization. Get